Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372(9635):293–9 https://doi.org//https://doi.org/10.1016/s0140-6736(08)61113-7

British HIV Association (BHIVA). Standards of Care for People Living with HIV 2018. Available from: https://www.bhiva.org/standards-of-care-2018.

National AIDS Trust. Providing coordinated care for people living with HIV [January 2020]. Available from: https://www.nat.org.uk/sites/default/files/Providing%20coordinated%20care%20briefing_0.pdf.

World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2023: WHO; 2022. Available from: https://iris.who.int/bitstream/handle/10665/360348/9789240053779-eng.pdf?sequence=1.

Lazarus, J. V., Safreed-Harmon, K., Barton, S. E., Costagliola, D., Dedes, N., Del Amo, V. J., Gatell, J. M., Baptista-Leite, R., Mendao, L., Porter, K., Vella, S., & Rockstroh, J. K. (2016). Beyond viral suppression of HIV—the new quality of life frontier. BMC Medicine, 14(1), 94. https://doi.org/10.1186/s12916-016-0640-4

Article  PubMed  PubMed Central  Google Scholar 

Ara, R., Brazier, J., & Zouraq, I. A. (2017). The use of health state utility values in decision models. PharmacoEconomics, 35(Suppl 1), 77–88. https://doi.org/10.1007/s40273-017-0550-0

Article  PubMed  Google Scholar 

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, GW. T. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.

Karimi, M., & Brazier, J. (2016). Health, health-related quality of life, and quality of life: What is the difference? PharmacoEconomics, 34(7), 645–649. https://doi.org/10.1007/s40273-016-0389-9

Article  PubMed  Google Scholar 

Wu, A. W., Jacobson, K. L., Frick, K. D., Clark, R., Revicki, D. A., Freedberg, K. A., Scott-Lennox, J., & Feinberg, J. (2002). Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Quality of Life Research, 11(3), 273–282. https://doi.org/10.1023/a:1015240103565

Article  CAS  PubMed  Google Scholar 

Tran, B. X., Ohinmaa, A., & Nguyen, L. T. (2012). Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health & Quality of Life Outcomes., 10, 132. https://doi.org/10.1186/1477-7525-10-132

Article  Google Scholar 

National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L value set for England 2019. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l#:~:text=Since%202008%2C%20our%20preferred%20measure,adults%20has%20been%20EQ%E2%80%915D.

Clayson, D. J., Wild, D. J., Quarterman, P., Duprat-Lomon, I., Kubin, M., & Coons, S. J. (2006). A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. PharmacoEconomics, 24(8), 751–765. https://doi.org/10.2165/00019053-200624080-00003

Article  PubMed  Google Scholar 

Cooper, V., Clatworthy, J., Harding, R., & Whetham, J. (2017). Measuring quality of life among people living with HIV: A systematic review of reviews. Health and Quality of Life Outcomes, 15(1), 220. https://doi.org/10.1186/s12955-017-0778-6

Article  PubMed  PubMed Central  Google Scholar 

Tran, B. X., Nguyen, L. H., Ohinmaa, A., Maher, R. M., Nong, V. M., & Latkin, C. A. (2015). Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: A systematic review and meta-analysis. BMC Health Services Research, 15, 7. https://doi.org/10.1186/s12913-014-0640-z

Article  PubMed  PubMed Central  Google Scholar 

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71

Article  PubMed  PubMed Central  Google Scholar 

Brazier, J., Ara, R., Azzabi, I., Busschbach, J., Chevrou-Séverac, H., Crawford, B., Cruz, L., Karnon, J., Lloyd, A., Paisley, S., & Pickard, A. S. (2019). Identification, review, and use of health state utilities in cost-effectiveness models: An ISPOR good practices for outcomes research task force report. Value Health., 22(3), 267–275. https://doi.org/10.1016/j.jval.2019.01.004

Article  PubMed  Google Scholar 

Centre for Reviews and Dissemination. CRD’s guidance for undertaking reviews in health care: University of York; 2009.

Papaioannou D, Brazier J, Paisley S. NICE DSU Technical Support Document 9: The identification, review and synthesis of health state utility values from the literature 2010. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/TSD9-HSUV-values_FINAL.pdf.

National Institute for Health and Care Research (NIHR). Health state utility values in people living with human immunodeficiency virus (PLWH) - a systematic review: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=346286; 2022. Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=346286.

National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual: process and methods 2022. Available from: https://www.nice.org.uk/process/pmg36/chapter/economic-evaluation.

Cooper, J. T., Lloyd, A., Sanchez, J. J. G., Sörstadius, E., Briggs, A., & McFarlane, P. (2020). Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: A systematic literature review. Health and Quality of Life Outcomes., 18(1), 310. https://doi.org/10.1186/s12955-020-01559-x

Article  PubMed  PubMed Central  Google Scholar 

Kennedy-Martin, M., Slaap, B., Herdman, M., van Reenen, M., Kennedy-Martin, T., Greiner, W., Busschbach, J., & Boye, K. S. (2020). Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. The European Journal of Health Economics, 21(8), 1245–1257. https://doi.org/10.1007/s10198-020-01195-8

Article  PubMed  PubMed Central  Google Scholar 

Rowen, D., Azzabi Zouraq, I., Chevrou-Severac, H., & van Hout, B. (2017). International regulations and recommendations for utility data for health technology assessment. PharmacoEconomics, 35(Suppl 1), 11–19. https://doi.org/10.1007/s40273-017-0544-y

Article  PubMed  Google Scholar 

Ahmed, A., Saqlain, M., Bashir, N., Dujaili, J., Hashmi, F., Mazhar, F., Khan, A., Jabeen, M., Blebil, A., & Awaisu, A. (2021). Health-related quality of life and its predictors among adults living with HIV/AIDS and receiving antiretroviral therapy in Pakistan. Quality of Life Research, 30(6), 1653–1664. https://doi.org/10.1007/s11136-021-02771-y

Article  PubMed  PubMed Central  Google Scholar 

Anderson, S. J., Murray, M., Cella, D., Grossberg, R., Hagins, D., Towner, W., Wang, M., Clark, A., Pierce, A., Llamoso, C., Ackerman, P., & Lataillade, M. (2022). Patient-reported outcomes in the phase III BRIGHTE trial of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals. The Patient: Patient-Centered Outcomes Research., 15(1), 131–143. https://doi.org/10.1007/s40271-021-00534-y

Article  PubMed  Google Scholar 

Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST, Team O. (2009). Quality of life of patients with advanced HIV/AIDS: Measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. Journal of Acquired Immune Deficiency Syndromes: JAIDS., 51(5), 631–639. https://doi.org/10.1097/QAI.0b013e3181a4f00d

Article  Google Scholar 

Anosike, C., Anene-Okeke, C. G., & Akunne, M. O. (2021). Assessment of health-related quality of life among patients infected With HIV receiving care in a Nigerian Tertiary Hospital. Value in Health Regional Issues., 25, 1–6. https://doi.org/10.1016/j.vhri.2020.09.002

Article  PubMed  Google Scholar 

Bansback, N., Sun, H., Guh, D. P., Li, X., Nosyk, B., Griffin, S., Barnett, P. G., & Anis, A. H. (2008). Impact of the recall period on measuring health utilities for acute events. Health Economics, 17(12), 1413–1419. https://doi.org/10.1002/hec.1351

Article  PubMed  Google Scholar 

Belay, Y. B., Ali, E. E., Sander, B., & Gebretekle, G. B. (2021). Health-related quality of life of patients with HIV/AIDS at a tertiary care teaching hospital in Ethiopia. Health & Quality of Life Outcomes., 19(1), 24. https://doi.org/10.1186/s12955-021-01670-7

Article  Google Scholar 

Castro, R., De Boni, R. B., Luz, P. M., Velasque, L., Lopes, L. V., Medina-Lara, A., Cardoso, S. W., De Oliveira, M. S., Friedman, R. K., Grinsztejn, B., & Veloso, V. G. (2019). Health-related quality of life assessment among people living with HIV in Rio de Janeiro, Brazil: A cross-sectional study. Quality of Life Research, 28(4), 1035–1045. https://doi.org/10.1007/s11136-018-2044-8

Article  PubMed  Google Scholar 

ClinicalTrials.gov. [NCT00255099] TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options 2005. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00255099.

ClinicalTrials.gov. [NCT02831764] An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (GEMINI-2) 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02831764.

ClinicalTrials.gov. [NCT02831673] An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (GEMINI-1) 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02831673

Delate, T., & Coons, S. J. (2001). The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clinical Infectious Diseases, 32(3), E47-52. https://doi.org/10.1086/318492

Article  CAS  PubMed  Google Scholar 

Gow, J., George, G., & Govender, K. (2013). A comparison of quality of life between HIV positive and negative diamond miners in South Africa. SAHARA J: Journal of Social Aspects of HIV/AIDS Research Alliance., 10(2), 89–95. https://doi.org/10.1080/17290376.2013.870066

Article  PubMed  Google Scholar 

Honiden, S., Sundaram, V., Nease, R. F., Holodniy, M., Lazzeroni, L. C., Zolopa, A., & Owens, D. K. (2006). The effect of diagnosis with HIV infection on health-related quality of Life. Quality of Life Research, 15(1), 69–82. https://doi.org/10.1007/s11136-005-8485-x

Article  PubMed  Google Scholar 

Huang, I. C., Willke, R. J., Atkinson, M. J., Lenderking, W. R., Frangakis, C., & Wu, A. W. (2007). US and UK versions of the EQ-5D preference weights: Does choice of preference weights make a difference? Quality of Life Research, 16(6), 1065–1072. https://doi.org/10.1007/s11136-007-9206-4

Article  PubMed